Title : Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma.

Pub. Date : 2017 Aug

PMID : 28627705






6 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma. Sorafenib DNA methyltransferase 1 Homo sapiens
2 Our data indicated that highly upregulated DNMT1 was positively correlated with PD-L1 overexpression in sorafenib-resistant HCC cells. Sorafenib DNA methyltransferase 1 Homo sapiens
3 Moreover, inactivation of NFkappaB blocked PD-L1/STAT3/DNMT1 pathway in sorafenib-resistant HCC cells. Sorafenib DNA methyltransferase 1 Homo sapiens
4 Functionally, genetic or pharmacological disruption of PD-L1 or/and DNMT1 sensitize HCC resistance to sorafenib. Sorafenib DNA methyltransferase 1 Homo sapiens
5 Importantly, dual inactivation of PD-L1 and DNMT1 by their inhibitor synergistically disrupts the colony formation of sorafenib-resistant HCC cells. Sorafenib DNA methyltransferase 1 Homo sapiens
6 These results demonstrate that targeting NFkappaB/PDL1/STAT3/DNMT1 axis is a new therapeutic strategy for preventing or overcoming the acquired resistance to sorafenib in HCC patients. Sorafenib DNA methyltransferase 1 Homo sapiens